Quick Answer
Acrivon Therapeutics, Inc. reported Shares Outstanding of 31.65 million shares for fiscal year 2025.
Acrivon Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 31.65M | +1.3% |
| 2024 | 31.23M | +38.7% |
| 2023 | 22.52M | +2.7% |
| 2022 | 21.92M | +1138.7% |
| 2021 | 1.77M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 31.55M | +1.3% | +0.3% |
| June 30, 2025 | 31.45M | +1.6% | +0.3% |
| March 31, 2025 | 31.35M | +38.5% | +0.4% |
| December 31, 2024 | 31.23M | +38.7% | +0.3% |
| September 30, 2024 | 31.13M | +40.8% | +0.5% |
| June 30, 2024 | 30.97M | +40.3% | +36.8% |
| March 31, 2024 | 22.64M | +3.3% | +0.5% |
| December 31, 2023 | 22.52M | +2.7% | +1.9% |
- Acrivon Therapeutics, Inc. showed an increase of +1.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2021–2025 period, Acrivon Therapeutics, Inc.’s shares outstanding has grown by 1688.5% (from 1.77 million shares to 31.65 million shares).
- The most recent figure is from Acrivon Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: